| # | Title | Journal | Year | Citations |
|---|
| 1 | The size and burden of mental disorders and other disorders of the brain in Europe 2010 | European Neuropsychopharmacology | 2011 | 2,930 |
| 2 | Exploring the brain network: A review on resting-state fMRI functional connectivity | European Neuropsychopharmacology | 2010 | 2,656 |
| 3 | Cost of disorders of the brain in Europe 2010 | European Neuropsychopharmacology | 2011 | 1,253 |
| 4 | Size and burden of mental disorders in Europe—a critical review and appraisal of 27 studies | European Neuropsychopharmacology | 2005 | 1,179 |
| 5 | Functional anatomical correlates of antidepressant drug treatment assessed using PET measures of regional glucose metabolism | European Neuropsychopharmacology | 2002 | 516 |
| 6 | Size of burden of schizophrenia and psychotic disorders | European Neuropsychopharmacology | 2005 | 516 |
| 7 | Inflammation and clinical response to treatment in depression: A meta-analysis | European Neuropsychopharmacology | 2015 | 489 |
| 8 | Prevalence and incidence of Parkinson's disease in Europe | European Neuropsychopharmacology | 2005 | 461 |
| 9 | Omega-3 fatty acids in major depressive disorder | European Neuropsychopharmacology | 2003 | 448 |
| 10 | Magnetic resonance imaging studies in unipolar depression: Systematic review and meta-regression analyses | European Neuropsychopharmacology | 2012 | 435 |
| 11 | Live fast, die young? A review on the developmental trajectories of ADHD across the lifespan | European Neuropsychopharmacology | 2018 | 398 |
| 12 | Regulation of adult neurogenesis by stress, sleep disruption, exercise and inflammation: Implications for depression and antidepressant action☆ | European Neuropsychopharmacology | 2010 | 391 |
| 13 | Herbal medicine for depression, anxiety and insomnia: A review of psychopharmacology and clinical evidence | European Neuropsychopharmacology | 2011 | 372 |
| 14 | Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET) | European Neuropsychopharmacology | 1997 | 359 |
| 15 | A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence | European Neuropsychopharmacology | 2013 | 359 |
| 16 | Treatment resistant depression: methodological overview and operational criteria | European Neuropsychopharmacology | 1999 | 354 |
| 17 | The hippocampal–prefrontal pathway: The weak link in psychiatric disorders? | European Neuropsychopharmacology | 2013 | 354 |
| 18 | The impact of stress on addiction | European Neuropsychopharmacology | 2003 | 346 |
| 19 | Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD | European Neuropsychopharmacology | 2009 | 323 |
| 20 | Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F]fluorodeoxyglucose (FDG) | European Neuropsychopharmacology | 1997 | 320 |
| 21 | Guidelines for depot antipsychotic treatment in schizophrenia | European Neuropsychopharmacology | 1998 | 299 |
| 22 | Size and burden of social phobia in Europe | European Neuropsychopharmacology | 2005 | 287 |
| 23 | Development and validation of a social functioning scale, the Social Adaptation Self-evaluation Scale | European Neuropsychopharmacology | 1997 | 285 |
| 24 | Stress resilience during the coronavirus pandemic | European Neuropsychopharmacology | 2020 | 285 |
| 25 | Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy | European Neuropsychopharmacology | 2012 | 283 |
| 26 | Prevalence and burden of bipolar disorders in European countries | European Neuropsychopharmacology | 2005 | 282 |
| 27 | The motivation and pleasure dimension of negative symptoms: Neural substrates and behavioral outputs | European Neuropsychopharmacology | 2014 | 273 |
| 28 | Placebo-controlled trial of agomelatine in the treatment of major depressive disorder | European Neuropsychopharmacology | 2006 | 270 |
| 29 | Increased serum tumor necrosis factor alpha concentrations in major depression and multiple sclerosis | European Neuropsychopharmacology | 2001 | 267 |
| 30 | Why are depressed patients inflamed? A reflection on 20 years of research on depression, glucocorticoid resistance and inflammation | European Neuropsychopharmacology | 2017 | 267 |
| 31 | Brain circuitry of compulsivity | European Neuropsychopharmacology | 2016 | 264 |
| 32 | Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension study | European Neuropsychopharmacology | 1998 | 260 |
| 33 | International consensus statement on attention-deficit/hyperactivity disorder (ADHD) and disruptive behaviour disorders (DBDs): Clinical implications and treatment practice suggestions | European Neuropsychopharmacology | 2004 | 260 |
| 34 | Negative symptoms of schizophrenia: Clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment | European Neuropsychopharmacology | 2014 | 255 |
| 35 | Blood serotonin levels in autism spectrum disorder: A systematic review and meta-analysis | European Neuropsychopharmacology | 2014 | 251 |
| 36 | A detailed examination of cytokine abnormalities in Major Depressive Disorder | European Neuropsychopharmacology | 2008 | 249 |
| 37 | Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial | European Neuropsychopharmacology | 1997 | 247 |
| 38 | Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial | European Neuropsychopharmacology | 2004 | 245 |
| 39 | Transcranial magnetic stimulation of dorsolateral prefrontal cortex reduces cocaine use: A pilot study | European Neuropsychopharmacology | 2016 | 245 |
| 40 | Neuroadaptive mechanisms of addiction: studies on the extended amygdala | European Neuropsychopharmacology | 2003 | 243 |
| 41 | High dose hydrocortisone immediately after trauma may alter the trajectory of PTSD: Interplay between clinical and animal studies | European Neuropsychopharmacology | 2011 | 243 |
| 42 | Type 3 diabetes is sporadic Alzheimer׳s disease: Mini-review | European Neuropsychopharmacology | 2014 | 237 |
| 43 | Cognitive impairments four months after COVID-19 hospital discharge: Pattern, severity and association with illness variables | European Neuropsychopharmacology | 2021 | 237 |
| 44 | Long-term efficacy and safety of donepezil in the treatment of Alzheimer’s disease: final analysis of a US multicentre open-label study | European Neuropsychopharmacology | 2000 | 236 |
| 45 | Antidepressant treatment prevents chronic unpredictable mild stress-induced anhedonia as assessed by ventral tegmentum self-stimulation behavior in rats | European Neuropsychopharmacology | 1992 | 230 |
| 46 | Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens | European Neuropsychopharmacology | 2016 | 229 |
| 47 | Architectonics of the human cerebral cortex and transmitter receptor fingerprints: reconciling functional neuroanatomy and neurochemistry | European Neuropsychopharmacology | 2002 | 222 |
| 48 | The pharmacology of putative early-onset antidepressant strategies | European Neuropsychopharmacology | 2003 | 219 |
| 49 | Facilitation of contextual fear memory extinction and anti-anxiogenic effects of AM404 and cannabidiol in conditioned rats | European Neuropsychopharmacology | 2008 | 219 |
| 50 | The cannabinoid CB2 receptor-selective phytocannabinoid beta-caryophyllene exerts analgesic effects in mouse models of inflammatory and neuropathic pain | European Neuropsychopharmacology | 2014 | 219 |
